ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM

Final data from LATITUDE study show switch to long-acting injectable treatment reduced the risk of virological failure by nearly half.

#	Наименование новости	Информативность	Дата публикации
1	Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026	14.8	29-07-2026
2	ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen	16.99	25-02-2026
3	ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV	13.56	27-07-2026
4	ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing	15.03	25-02-2026
5	Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis B	14.39	27-03-2026
6	Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B	12.98	30-03-2026
7	Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B	7.23	24-08-2026
8	Bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B	10.98	26-02-2026
9	Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA	6.94	28-04-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 12.86. Источник: www.gsk.com.

Найдите то, что Вас интересует